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Abstract
Background: Nicotine is the major addictive component of tobacco smoke. Although nicotine is generally thought to have
limited ability to initiate cancer, it can induce cell proliferation and angiogenesis in a variety of systems. These properties
might enable nicotine to facilitate the growth of tumors already initiated. Here we show that nicotine significantly promotes
the progression and metastasis of tumors in mouse models of lung cancer. This effect was observed when nicotine was
administered through intraperitoneal injections, or through over-the-counter transdermal patches.
Methods and Findings: In the present study, Line1 mouse adenocarcinoma cells were implanted subcutaneously into
syngenic BALB/c mice. Nicotine administration either by intraperitoneal (i.p.) injection or transdermal patches caused a
remarkable increase in the size of implanted Line1 tumors. Once the tumors were surgically removed, nicotine treated mice
had a markedly higher tumor recurrence (59.7%) as compared to the vehicle treated mice (19.5%). Nicotine also increased
metastasis of dorsally implanted Line1 tumors to the lungs by 9 folds. These studies on transplanted tumors were extended
to a mouse model where the tumors were induced by the tobacco carcinogen, NNK. Lung tumors were initiated in A/J mice
by i.p. injection of NNK; administration of 1 mg/kg nicotine three times a week led to an increase in the size and the number
of tumors formed in the lungs. In addition, nicotine significantly reduced the expression of epithelial markers, E-Cadherin
and b-Catenin as well as the tight junction protein ZO-1; these tumors also showed an increased expression of the a7 nAChR
subunit. We believe that exposure to nicotine either by tobacco smoke or nicotine supplements might facilitate increased
tumor growth and metastasis.
Conclusions: Our earlier results indicated that nicotine could induce invasion and epithelial-mesenchymal transition (EMT)
in cultured lung, breast and pancreatic cancer cells. This study demonstrates for the first time that administration of nicotine
either by i.p. injection or through over-the-counter dermal patches can promote tumor growth and metastasis in
immunocompetent mice. These results suggest that while nicotine has only limited capacity to initiate tumor formation, it
can facilitate the progression and metastasis of tumors pre-initiated by tobacco carcinogens.
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Introduction
Tobacco smoke contains a wide array of compounds that are
deleterious to health; some of these compounds such as 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N’-ni-
trosonornicotine (NNN) are nicotine derivatives and are highly
carcinogenic [1]. These molecules can form adducts with cellular
DNA, leading to mutations in vital genes like Ras, p53, and Rb
[2,3,4]. While nicotine is the addictive component in cigarette
smoke, it cannot initiate tumor formation in mice or rats, though it
has been reported that it can initiate tumors in hamsters [5].
Nicotine exerts its cellular functions through nicotinic acetyl-
choline receptors (nAChRs), which are widespread in neurons and
neuromuscular junctions [6,7,8]. nAChR subunits were found to
be present in a wide variety of non-neuronal cells, including those
of epithelial and endothelial origin [9]. nAChRs are pentameric
proteins consisting of nine a subunits (a2–a10) and three b
subunits (b2–b4) in neuronal cells [10] and can be grouped into
two types- one comprising of a heteromeric pentamer of a2–a6
and b2–b4, and the other comprising of a homomeric pentamer of
a7–a9 [11,12,13]. Non-neuronal (muscle type) receptors are
composed of either a1, b1, d and c subunits in the embryonic
form, or as a1, b1, d and e subunits in the adult form in a 2:1:1:1
ratio [14]. Both muscle and neuronal type receptors are somewhat
similar to one another, especially in the hydrophobic regions.
They differ in their sensitivity to a-bungarotoxin (a-BT) [13,15].
a7 nAChR is abundant in neuronal cells, has high permeability to
Ca
2+ thereby facilitating Ca
2+-dependent events such as neuro-
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[16,17], cell survival [18] and apoptosis [19]. The finding that
nAChRs are present on non-neuronal cells was followed by the
observation that nicotine could induce the proliferation of
endothelial cells [20] as well as lung carcinoma cell lines in vitro
and in vivo [21]. Nicotine has also been shown to protect lung
cancer cells from apoptosis induced by standard chemotherapeutic
drugs [22]; in addition, nicotine could induce proliferation
through the mediation of b-arrestin-1, Src kinase and the
induction of Rb-Raf-1 interaction [23,24].
Recent studies from the Russo lab has shown that inhibition of
nAChRs by a-cobratoxin can inhibit the growth of A549 tumors in
immunocompromised mice [25]. Recent reports have also
demonstrated the presence of functional estrogen receptors in lung
cancer cell lines; estradiol has been shown to promote lung tumor
cell proliferation [26,27,28,29] and a combination of nicotine and
estradiol can promote the growth of A549 tumors in athymic nude
mice [30]. These reports present studies done on immunodeficient
mice; we ventured to study the effect of nicotine on two separate
models of immunocompetent mice. Studies presented here show
that nicotine by itself can induce the growth and metastasis of
tumors in immunocompetent mice, independent of other tobacco
carcinogens. Nicotine administered either intraperitoneally or by
commercially available transdermal patches could substantially
promote tumor growth. Similar effects were observed on implanted
tumors as well as tumors induced by the tobacco carcinogen, NNK.
Further, mice exposed to nicotine showed significantly enhanced
lung metastasis as well as tumor recurrence post surgical removal of
the primary tumor. These results imply that nicotine can enhance
the growth and metastasis of pre-established lung tumors.
Methods
Cell Culture and Proliferation assays
Line1 cells were cultured in RPMI (MediaTech) containing 10%
FBS. Line1 cells were plated in poly-D-lysine coated chamber slides at
a density of 10,000 cells per well and rendered quiescent by serum
starvation for 72 h. Cells were then re-stimulated with nicotine for
1 8hi nt h ep r e s e n c eo ra b s e n c eo f1 0mM a-BT, an a7 receptor
antagonist. Cell proliferation was assessed by measuring BrdU
incorporation. Bromodeoxyuridine (BrdU) labeling kits were obtained
from Roche Biochemicals. S-phase cells were visualized by micros-
copy and quantitated by counting 3 fields of 100 in quadruplicate.
Line1 Tumor Growth Experiments
Female BALB/c mice aged 26–30 days (Charles River) were
clipped and depilated using Nair for hair removal on the back and
flanks. Line1 cells (1610
6 per tumor) were harvested and
resuspended in 100 ml of PBS for injection. The mice were
randomized 3–7 days after injection of tumor cells. Mice were
separated into two groups- Vehicle (n=8) and Nicotine (n=8)
(patch or i.p. injection). Mice received nicotine by i.p. injection at
a dose of 1 mg/kg three times a week. Nicotine was also applied
using transdermal patches (NicoHDermH CQ, GlaxoSmithKline)
at a dose of 25 mg/kg daily. Patches (14 mg) were cut into 30
equal sized squares representing 0.45 mg of nicotine using a razor
blade. The average weight of the mice was 0.018 Kg (18 g). A
small square representing 0.45 mg of the patch equaled a final
dose of 25 mg/kg daily. One patch was applied to the lower dorsal
area (depilated) per day. Nicotine was administered for 2 weeks
and tumor growth was measured thrice weekly. Nicotine levels in
mice were analyzed using a cotinine ELISA kit (cat # CT086D;
CalBiotech, Spring Valley, CA).
Line1 metastasis experiments
Line1 cells (1610
6 per tumor) were injected and the mice were
subsequently randomized into two groups. Group one received the
vehicle (n=16) and group two received nicotine (1 mg/kg) (n=16)
by i.p. injection thrice weekly. After 3 weeks of nicotine treatment,
the tumors were removed under anesthesia and the skin was
stapled, mice recovered on a warmed heating pad and the staples
were removed after 7 days. Mice continued to receive nicotine or
vehicle for an additional 2 weeks. At the end of the experiment, the
mice were euthanized and the lungs were fixed in formalin.
A/J tumorigenicity experiments
Two experiments were carried out using female A/J mice 4–6
weeks of age (Jackson Labs). The mice were maintained in
accordance with Institutional Animal Care and Use Committee
(IACUC) procedures and guidelines. NNK (NCI) (100 mg/kg) was
administered to all mice (n=16) once a week for 5 weeks [31,32].
The mice were randomized into two groups; group one received
the vehicle (PBS) (n=8) and group two received nicotine (n=8)by
i.p. injection at a dose of 1 mg/kg three times a week for an
additional 28 weeks. Nicotine levels in mice were analyzed using a
cotinine ELISA kit. At the end of the experiment, the mice were
euthanized and the lungs were fixed in 10% buffered formalin.
The lungs were subsequently examined by stereoscope for number
of lung tumors. The lungs were paraffin embedded and sectioned
for IHC staining and pathological examination.
Quantitation of Cotinine
Level of cotinine in urine was used as a marker for nicotine
levels. Urine (100 ml) was collected throughout the length of the
experiments and stored in 220uC for later analysis. Cotinine levels
were determined by using the BioQuant Cotinine Direct ELISA
kit following manufacturer’s protocols.
RT-PCR
Reverse transcriptase coupled PCR was done for a7 nAChR on
Line1 cells. Total RNA was isolated from serum starved and
nicotine stimulated Line1 cells (RNEasy Kit; Qiagen) by using the
manufacturer’s protocol. cDNA was synthesized by reverse
transcription by using an AMV-RT kit (Promega). The primers
and conditions for RT-PCR for a7 nAChR were described
elsewhere [23,33]. PCR for actin was used as the loading control.
Noradrenaline and Adrenaline ELISAs
Line1cellswere renderedquiescent by serumstarvationand treated
with 1 mM nicotine for 48 h. After which, the media was collected and
diluted appropriately to assess the noradrenaline and adrenaline
secreted into the media. The ELISA was done using adrenaline
research ELISA and noradrenaline research ELISA kits from Labor
Diagnostika Nord (cat# BA 10–5100 and BA 10–5200 respectively)
by following the manufacturer’s protocol. The concentrations were
reached at by following the calculations suggested in the protocol and
the values are representative of two independent experiments.
Immunohistochemistry
Upon termination of animal experiments, tumors were removed
and fixed in 10% neutral-buffered formalin before processing into
paraffin blocks. Tissue sections (5 mm thick) were cut from the
blocks and stained either with H&E alone or with antibodies
against a7 nAChR (1:50 dilution, Abcam), E-Cadherin (1:200
dilution, Santa Cruz), b-Catenin (1:200 dilution, Santa Cruz) or
ZO-1 (1:200 dilution, Abcam). For immunohistochemical studies,
paraffin sections were rehydrated to PBS and processed using the
Nicotine Promotes Metastasis
PLoS ONE | www.plosone.org 2 October 2009 | Volume 4 | Issue 10 | e7524followingprotocol.SectionswererinsedindH2O,andthensubjected
to microwave ‘antigen retrieval’ for 20 minutes on 70% power, with a
1 minute cooling period after every 5 minutes, in 0.01 M sodium
citrate,pH 6.0.Sections werecooled for 20 minutes,rinsed 3times in
dH2O, twice in PBS and the rest of the staining was done following
the manufacturer’s protocol (Universal Elite ABC kit, Vector labs).
For color development the slides were treated with peroxidase
substrate kit from Vector labs (cat # SK-4100) and developed using
DAB as chromogen. After a final rinsein dH2O, sections werelightly
counterstained in hematoxylin, dehydrated and mounted with
Clarion mounting medium (Santa Cruz Biotech.). Both H&E and
immunohistochemically stained slides were scanned on an Ariol SL-
50 (version 3.0.70) Automatic Scanning System from Applied
Imaging. Tumor sections were scanned at 206magnification and
the regions of interest were identified and outlined by a pathologist
(DC). The tumor sections with immunopositive regions from control
and treated mice were quantified for intensity, size and area using
Ariol software Review Station. p value was determined for statistical
significance with the help of student’s t-test.
Results
Nicotine promotes the growth of tumors in mice
The proliferative and pro-angiogenic effects of nicotine have
been shown in multiple systems; recent studies had shown that
nicotine could promote the growth of A549 (lung adenocarcinoma
cells of type II alveolar phenotype) tumors in immunodeficient
mice [25]. To determine the effects of nicotine on tumor growth
and metastasis in immunocompetent mice, Line1 mouse adeno-
carcinoma cells were utilized. Line1 cells form subcutaneous (s.c.)
tumors in BALB/c mice, which can metastasize to the lungs
[34,35,36,37,38]. To examine whether nicotine induced prolifer-
ation of Line1 cells, the cells were serum starved for 72 hours and
subsequently stimulated with 1 mM nicotine for 18 hours. S-phase
entry was measured using BrdU incorporation assays. Nicotine
could efficiently stimulate Line1 cells to enter S-phase (Figure 1A).
Next, Line1 cells were implanted into the flanks of BALB/c mice
and allowed to form tumors. The mice were randomized into two
groups, with one group receiving vehicle (n=8) and the second
receiving 1 mg/kg nicotine (n=8) thrice weekly by intraperitoneal
(i.p.) injection. Mice that received nicotine had significantly larger
tumors compared to those receiving vehicle; tumor volumes
averaged 695698 mm
3 in vehicle treated mice, compared to
22676369 mm
3 in nicotine treated mice (Figure 1B), p=0.002.
Based on the above results, experiments were done to examine
whether nicotine administered by over-the-counter transdermal
patches could promote tumor growth. BALB/c mice (n=16)
implanted with Line 1 tumors were randomized into two groups and
nicotine patches were applied daily at a dose of 25 mg/kg nicotine. It
was found that nicotine administered by transdermal patches could
significantly increase the growth of Line1 tumors; control mice had an
average tumor volume of 530659 mm
3 while mice wearing nicotine
patches had an average volume of 8716106 mm
3 (Figure 1C),
p=0.019. These experiments confirm that exposure to nicotine, even
through nicotine supplements, might affect pre-established tumors.
Nicotine promotes re-growth and metastasis of tumors
in mice
Since nicotine was found to enhance tumor growth, experiments
were conducted to assess its effects on tumor metastasis. In order to
examine this, the implanted tumors were surgically removed after 14
days of treatment or once they reached 500–700 mm
3.T u m o r sw e r e
Figure1.NicotinepromotesthegrowthofLine1cells.(A) Nicotine (1 mM) promotes S-phase entry of serum starved Line1 cells in BrdU incorporation
assays. (B) Nicotine (1 mg/kg) significantly increases Line1 tumor growth in Balb/c mice when administered by i.p. injection thrice weekly, p=0.002,n=1 0 .
(C) Nicotine (25 mg/kg/daily) also significantly increases Line1 tumor growth when administered by transdermal patches p=0.019, n=14.
doi:10.1371/journal.pone.0007524.g001
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anesthetized for tumor removal, and wounds were stapled close. After
t h et u m o rr e m o v a l ,m i c ew e r ea d m i n i s t e r e dv e h i c l eo rn i c o t i n eb yi . p .
injection for an additional 14 days. Interestingly, mice treated with
nicotine showed a higher rate of tumor recurrence after the tumors
were surgically removed (Figure 2A); vehicle treated mice displayed an
Figure 2. Nicotine increases metastatic potential. (A) Nicotine treated mice (1 mg/kg) displayed higher incidence of tumor recurrence following
surgical removal of tumors compared to the vehicle control group, p=0.01, n=16. (B) Nicotine treated mice display significantly more lung metastasis
from primary Line1 s.c. tumors. (C)H&E staining of lungs from vehicle andnicotine treated mice, nicotine treated mice display larger tumors as indicated
by arrows. (D) Graph displaying the averagetotal number of lung tumors per mouse in vehicle andnicotine (1 mg/kg) treated mice, p=0.001, n=16. (E)
Graph displaying the average total number of lung tumors per mouse in control and nicotine patch (25 mg/kg) treated mice, p=0.02, n=16.
doi:10.1371/journal.pone.0007524.g002
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5963 %tu m o rr e c u r r e n c ei nn i c o t i n e( 1m g / k g )tr e at e dm i c e ,p=0.01,
n=16. Tumor recurrence was calculated as percentage of recurring
tumors out of the total number of tumors removed. As shown in
Figure 2B, nicotine treated mice also displayed significantly greater
number of lung metastases as well as larger metastatic foci compared to
those receiving vehicle. Histologic examination of the lung tumors
confirmed larger metastatic foci in the nicotine treated mice
(Figure 2C). Mice receiving the vehicle had an average of 0.960.2
metastatic foci in the lungs per mouse; in comparison, mice that
received nicotine at a dosage of 1 mg/kg thrice weekly had an average
of 8.161.7 foci in the lungs per mouse, p=0.001, n=16(Figure2D).
Interestingly, mice receiving nicotine through dermal patches had an
average of 20.664.9 lung metastatic foci per mouse while mice
receiving vehicle had an average of 6.762.1 foci per mouse (p=0.02,
n=16) (Figure 2E).
Cotinine, a major metabolite of nicotine, is currently considered
the best indicator of tobacco smoke exposure [39]. It is specific for
nicotine, has a long half-life (15–40 hours), and its level is thought
to be directly proportional to the quantity of absorbed nicotine
[40]. Hence to determine the concentration of nicotine in our
mouse models, we examined cotinine levels in the urine of the
experimental mice. Urine (100 ml) was routinely collected
throughout the length of the experiments. Mice receiving 1 mg/kg
nicotine thrice weekly had an average cotinine concentration of
3000 ng/ml in urine. Mice that received 25 mg/kg nicotine by
transdermal patch had an average cotinine concentration of
5000 ng/ml cotinine in their urine. Cotinine levels in urine were
often in a wide range of concentration due to the variance of urine
collection volumes. In human smokers, cotinine concentrations
have been reported in values ranging from 1500 ng/ml to
8000 ng/ml [41,42,43,44]. Nicotine doses used in these studies
correlated well with cotinine levels in the urine of heavy smokers
[42,43].
Nicotine enhances the growth of tumors induced by
tobacco carcinogens
Experiments were designed to examine the effects of nicotine
on tumors induced by the tobacco carcinogen, NNK; this
experimental system mimics a situation where tumors are
initiated by a carcinogen, followed by exposure to nicotine alone.
Towards this purpose, A/J mice were treated with 100 mg/kg
NNK once a week for five weeks to initiate tumor formation and
subsequently they were randomized into two groups. One group
of mice received the vehicle (PBS) whilst the second group
received nicotine (1 mg/kg) thrice weekly by i.p. injection; mice
were treated with nicotine or vehicle for 28 weeks. Lungs from
both vehicle and nicotine treated mice had developed tumors
(Figure 3A & B). H&E stained lung sections were scanned and a
pathologist (DC) outlined the tumor area; size and number of
tumor foci were quantitated. Mice that received PBS after NNK
injections had an average of 1063.0 lung tumors per section and
Figure 3. Nicotine increases number and size of NNK induced lung tumors. (A) H&E staining of transverse sectioning of lungs
(B) Representative scanned images of H&E stained coronal lung sections, tumors are outlined by boxes. Images were scanned at
206magnification. (C) Nicotine increases the average number of lung tumors per mouse, p=0.01, n=8. (D) Nicotine increased tumor size
significantly in A/J mice.
doi:10.1371/journal.pone.0007524.g003
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section, p=0.01, n=8 (Figure 3C). Tumor size (area) also
increased in nicotine treated mice (Figure 3D). This suggests that
exposure to nicotine once the tumors are already initiated can
result in enhanced tumor growth.
Nicotine induces cell proliferation via a7 nAChR subunit
in mouse lung cancer
In our previous report, we showed that nicotine could induce
proliferation and invasion of human NSCLCs via a7 nAChR
subunit [45]. In the present study, we found nicotine could induce
proliferation in mouse lung adenocarcinoma Line1 cells mainly via
a7 nAChR subunit. a-bungarotoxin, an a7 subunit antagonist
significantly inhibited nicotine-induced proliferation in Line1 cells,
thereby suggesting that a7 subunit is mainly responsible for
mediating the proliferative effect of nicotine (Figure 4A). To further
confirm the roleofa7 nAChR innicotine mediated cellproliferation
we performed RT-PCR for a7 nAChR subunit expression.
Treatment of Line1 cells with nicotine for 24 hours caused the
upregulation of a7 nAChR subunit with respect to serum-starved
cells, as shown in Figure 4B. We observed a similar increase in the
protein expression of a7 nAChR in lung tumor sections from A/J
mice treated with nicotine upon immunostaining (Figure 4C); the
results are quantified in Figure 4D. These results suggest that
exposure to nicotine is inducing cell proliferation and tumor growth
through the a7 subunit of nAChRs.
Nicotine has been shown to induce cell growth of colon and
gastric cancer cells via a7 nAChR-mediated release of adrenaline,
which in turn upregulates the expression of COX-2, PGE2 and
VEGF, thereby facilitating the progression of these cancers
[46,47,48]. Similarly, in our study we found that nicotine
treatment elevated the levels of adrenaline and noradrenaline in
mouse lung adenocarcinoma. Line1 cells were treated with
nicotine for 48 hours and the media was collected to check for
the release of adrenaline and noradrenaline. Nicotine elevated the
levels of adrenaline to 42.562.4 pg/ml from 1761 pg/ml in
control, while noradrenaline levels peaked to 3764.8 pg/ml when
compared to 6.760.87 pg/ml in control. These results suggest
that signaling through adrenaline might also contribute to the
observed proliferative effects of nicotine.
Nicotine facilitates EMT-like changes in lung cancers
Given the observation that nicotine can induce tumor growth
and promote metastasis [20,45,49], attempts were made to
Figure 4. Nicotine enhances a7 nAChR subunit expression in Line1 cells. (A) Quiescent Line1 cells were treated with 1 mM nicotine for 18 h
in the presence or absence of a-BT, an a7 nAChR subunit inhibitor. Nicotine enhances a7 expression, while a-BT reverses this. (B) Reverse-transcriptase
coupled-PCR showing the expression of a7 nAChR subunits in serum starved Line1 cells treated with nicotine for 24 h. PCR for actin was used as the
loading control. (C) a7 nAChR staining of A/J lung tumors induced by NNK or induced by NNK and exposed to Nicotine. Nicotine enhances the
expression of this receptor subunit. (D) Quantitation of a7 nAChR expression in vehicle and nicotine treated tumors.
doi:10.1371/journal.pone.0007524.g004
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Epithelial-mesenchymal transition (EMT) is a phenomenon by
which cells lose their epithelial phenotype and acquire more
mesenchymal features that facilitate detachment and migration
[50,51,52]. We examined the tumors in A/J mice for changes
consistent with an EMT-like phenomenon, using immunohisto-
chemical staining for E-cadherin and b-Catenin, two proteins
involved in the adhesion of epithelial cells. b-Catenin binds to E-
Cadherin to facilitate cell adhesion and to exert its signaling
functions. E-Cadherin levels were found to be significantly
decreased in the tumors of mice treated with nicotine
(Figure 5A); the results are quantified in Figure 5B. Staining for
b-Catenin, which binds to E-Cadherin to facilitate adhesion in
addition to its signaling functions [53], revealed loss of
membranous localization of b-Catenin in lung tumors from mice
treated with nicotine (Figure 5C & D). Moreover lung tumor
sections from nicotine treated mice showed significantly reduced
expression of ZO-1 upon immunostaining (Figure 5E & F). It was
consistent with our earlier findings on breast and lung cancer cells
that showed decreased membranous ZO-1 staining upon nicotine
treatment, thereby indicating that nicotine facilitates the disrup-
tion of tight junctions to promote metastasis [45].
Figure 5. Nicotine reduced the expression of epithelial markers in A/J mice. (A) E-Cadherin staining of A/J lung tumors induced by NNK or
NNK+nicotine. (B) Quantitation of E-Cadherin intensity in tumors (C) b-Catenin staining of A/J lung tumors induced by NNK or NNK+nicotine. (D)
Quantitation of membranous b-Catenin. (E) ZO-1 staining of A/J lung tumors induced by NNK or NNK+nicotine. (F) Quantitation of membranous ZO-1.
doi:10.1371/journal.pone.0007524.g005
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Several observations in patients suggest that those exposed to
tobacco carcinogens are more likely to develop larger, more
vascularized tumors with a high propensity for metastatic spread
and resistance to chemotherapy [54]. In addition, about 30% of
lung cancer patients who are smokers continue to smoke after
they have been diagnosed [38]. This is problematic, as smokers
who continue to use tobacco after a cancer diagnosis or return
to smoking experience increased adverse medical consequences,
such as: increased tumor progression, development of a second
cancer, greater recurrence following successful treatment,
greater cancer-related mortality and reduced quality of life
[55,56]. While these studies demonstrate a role for tobacco
carcinogens in the initiation, growth and progression of cancers,
the relative contribution of nicotine by itself to these processes is
not known. This is a significant aspect, since the use of nicotine
supplements is usually part of many cigarette smoking cessation
programs.
While nicotine has been demonstrated to induce cell prolifera-
tion, angiogenesis and growth of tumors [20], the studies presented
here show for the first time that nicotine patches can promote
tumor re-growth and metastasis. Further, our results show that the
presence of nicotine can enhance the growth of lung tumors
initiated by a tobacco carcinogen. Essentially, the A/J mouse model
is reflective of a situation where a smoker who has tumors initiated
in the lung quits smoking and uses nicotine supplements to
overcome the craving. Our results also show that a commercially
available nicotine transdermal patch can promote the growth of
tumors implanted into mice.
Our results as well as results from John Cooke’s lab show that
a7 receptor subunit is vital for nicotine-mediated cell proliferation
and Src function is indispensable for nicotine to induce
proliferation and angiogenesis [23,24]. Another study has
proposed the involvement of muscle-type nAChR subunits in
proliferation [57]. Interestingly, three different studies from
Europe showed a susceptibility locus for lung cancer that maps
to nicotinic acetylcholine receptor subunit genes on chromo-
some15q24-25 [58,59,60]; this locus contained genes for a3, a5
and b4 subunits. Variations within this loci were predominantly
found in smokers and correlated with smoking-related lung cancer
as well as other diseases like peripheral arterial disease [61]. These
recent studies raise the possibility that there is a direct correlation
between the status and probably function of nAChRs and the
onset as well as progression of lung cancer in smokers [62]. In
addition, it has been shown that NSCLCs from never smokers
express higher levels of a6b3 subunits whereas smokers show
higher expression of a1, a3 and a7 subunits and a lower
expression of a6b3 nAChR subunits [47]. Our studies presented
in this manuscript suggest that nicotine stimulation of nAChR, and
essentially activation of nAChR function, does indeed contribute
to the progression of lung cancers.
There are many signaling molecules that are known to be
activated by nAChR stimulation. These include activation of Src
kinase cascade, PI3-Akt pathway, ERK/MAP kinase cascade,
NFkB pathway as well as cyclic AMP signaling cascade. Further,
nicotine has been shown to function in collaboration with estradiol
[30]. These observations raise the possibility that a wide array of
signals emanating from these receptors affect various aspects of
tumor initiation, progression and metastatic spread. This scenario
also opens up the possibility that targeting one or more of these
pathways might be beneficial in combating such neoplasms.
The finding that epithelial adhesion molecules like E-Cadherin
and its binding partner b-Catenin are affected by nicotine provides
a molecular basis for these findings. It can be imagined that
nicotine, through the nAChR signaling pathways, induces change
in gene expression patterns to facilitate EMT and tumor
metastasis. Indeed, it has been reported that the expression
pattern of nAChR subunits is different in tumors from smokers
and never smokers [63,64]. Given the ability of nicotine to affect
various aspects of tumor growth and metastasis, it is possible that
antagonists of nAChR signaling might prove beneficial in
controlling the growth and progression of lung cancers; certain
studies support this contention [65]. Further, such agents that
modulate the function of nAChRs such as varenidine, an agonist
of a4b2 nAChRs, might be better alternatives for smoking
cessation than nicotine itself.
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